25.04.2016 • News

Valeant on Verge of Hiring Perrigo’s CEO?

In its search for a new CEO to replace William J. Pearson, who has resigned amid several controversies, Canada-domiciled  embattled drugmaker Valeant is said to be finalizing a contract with Joseph C. Papa, chairman and CEO of Ireland-domiciled pharmaceutical producer Perrigo. Neither of the companies – both managed from the US – has been willing to comment on the speculation launched by The Wall Street Journal, which said the appointment could be announced as early as this week.

Valeant is under heavy scrutiny in the US Senate for price gouging. It also is being subjected to a US federal government audit of its accounting and pricing practices, as well more than one Securities and Exchange Commission (SEC) investigation.

Among other things, the SEC is looking into issues at Salix Pharmaceuticals, which was acquired by Valeant for $11 billion in 2015.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.